Dynastat Pfizer Europe MA EEIG · Authorised · authorised 22 Mar 2002 · ATC M01AH04
Therapeutic indication (EMA)
For the short-term treatment of postoperative pain in adults.
Active substance
Parecoxib
- SFDA 2
- EMA 3
- NHS prices 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DYNASTAT 40 mg Powder And solvent for Solution For injection | 40 mg | Powder and solvent for solution for injection · Intramuscular and intravenous use | 5 Vial | SAR 177.90 | NCE · Prescription | Pfizer Europe MA EEIG | Valid |
| Parecoxib SPI | 40 mg | Powder and solvent for solution for injection · Intramuscular and intravenous use | 5 Vial | SAR 124.55 | Generic · Prescription | SAUDI PHARMACEUTICAL INDUSTRIES | Valid |
Indications — CHI Daman Drug Formulary
ACUTE PANCREATITIS-PAIN MANAGEMENT; DENTAL ABSCESS-DENTAL PAIN; ENDOMETRIOSIS; LOW BACK PAIN; PAIN MANAGEMENT IN CANCER PATIENTS; POSTOPERATIVE PAIN; RENAL AND URETERIC STONES
EMA European Union — centrally authorised medicines
Xapit Pharmacia Europe EEIG · Withdrawn · authorised 22 Mar 2002 · ATC M01AH04
Therapeutic indication (EMA)
For the short-term treatment of postoperative pain.
Rayzon Pharmacia Europe EEIG · Withdrawn · authorised 22 Mar 2002 · ATC M01AH04
Therapeutic indication (EMA)
For the short-term treatment of postoperative pain.The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risks (see sections 4.3, 4.4).
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Parecoxib 40mg powder and solvent for solution for injection vials | £28.34 | 5 vial | 1 Oct 2026 |
| NHS Drug Tariff | Parecoxib 40mg powder for solution for injection vials | £49.60 | 10 vial | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.